Literature DB >> 28235541

Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma.

Rosie Elizabeth Ann Gutteridge1, Chandra K Singh1, Mary Ann Ndiaye1, Nihal Ahmad2.   

Abstract

A limited number of studies have indicated an association of the mitotic kinase polo-like kinase 1 (PLK1) and cellular metabolism. Here, employing an inducible RNA interference approach in A375 melanoma cells coupled with a PCR array and multiple validation approaches, we demonstrated that PLK1 alters a number of genes associated with cellular metabolism. PLK1 knockdown resulted in a significant downregulation of IDH1, PDP2 and PCK1 and upregulation of FBP1. Ingenuity Pathway Analysis (IPA) identified that 1) glycolysis and the pentose phosphate pathway are major canonical pathways associated with PLK1, and 2) PLK1 inhibition-modulated genes were largely associated with cellular proliferation, with FBP1 being the key modulator. Further, BI 6727-mediated inhibition of PLK1 caused a decrease in PCK1 and increase in FBP1 in A375 melanoma cell implanted xenografts in vivo. Furthermore, an inverse correlation between PLK1 and FBP1 was found in melanoma cells, with FBP1 expression significantly downregulated in a panel of melanoma cells. In addition, BI 6727 treatment resulted in an upregulation in FBP1 in A375, Hs294T and G361 melanoma cells. Overall, our study suggests that PLK1 may be an important regulator of metabolism maintenance in melanoma cells. Published by Elsevier B.V.

Entities:  

Keywords:  Melanoma; Metabolism; Polo like kinase

Mesh:

Substances:

Year:  2017        PMID: 28235541      PMCID: PMC5415376          DOI: 10.1016/j.canlet.2017.02.013

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  32 in total

1.  Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.

Authors:  Meghan J Seltzer; Bryson D Bennett; Avadhut D Joshi; Ping Gao; Ajit G Thomas; Dana V Ferraris; Takashi Tsukamoto; Camilo J Rojas; Barbara S Slusher; Joshua D Rabinowitz; Chi V Dang; Gregory J Riggins
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

2.  Normal prostate-derived stromal cells stimulate prostate cancer development.

Authors:  Yu-Bing Peng; Juan Zhou; Yan Gao; Yu-Hua Li; Hao Wang; Ming Zhang; Li-Ming Ma; Qi Chen; Jun Da; Zhong Wang; Runsheng Li
Journal:  Cancer Sci       Date:  2011-07-28       Impact factor: 6.716

3.  Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state.

Authors:  Zhiguo Li; Jie Li; Pengpeng Bi; Ying Lu; Grant Burcham; Bennett D Elzey; Timothy Ratliff; Stephen F Konieczny; Nihal Ahmad; Shihuan Kuang; Xiaoqi Liu
Journal:  Mol Cell Biol       Date:  2014-07-21       Impact factor: 4.272

4.  Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage.

Authors:  N Takai; T Miyazaki; K Fujisawa; K Nasu; R Hamanaka; I Miyakawa
Journal:  Cancer Lett       Date:  2001-03-10       Impact factor: 8.679

5.  The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase.

Authors:  B V Geisbrecht; S J Gould
Journal:  J Biol Chem       Date:  1999-10-22       Impact factor: 5.157

6.  The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.

Authors:  Péter Lénárt; Mark Petronczki; Martin Steegmaier; Barbara Di Fiore; Jesse J Lipp; Matthias Hoffmann; Wolfgang J Rettig; Norbert Kraut; Jan-Michael Peters
Journal:  Curr Biol       Date:  2007-02-08       Impact factor: 10.834

7.  Association between FBP1 and hypoxia-related gene expression in clear cell renal cell carcinoma.

Authors:  Xiang-Hui Ning; Teng Li; Yan-Qing Gong; Qun He; Q I Shen; Shuang-He Peng; Jiang-Yi Wang; Jin-Chao Chen; Ying-Lu Guo; Kan Gong
Journal:  Oncol Lett       Date:  2016-04-27       Impact factor: 2.967

8.  Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells.

Authors:  Travis L Schmit; Weixiong Zhong; Vijayasaradhi Setaluri; Vladimir S Spiegelman; Nihal Ahmad
Journal:  J Invest Dermatol       Date:  2009-06-25       Impact factor: 8.551

Review 9.  From Plk1 to Plk5: functional evolution of polo-like kinases.

Authors:  Guillermo de Cárcer; Gerard Manning; Marcos Malumbres
Journal:  Cell Cycle       Date:  2011-07-15       Impact factor: 4.534

10.  The contributions of HIF-target genes to tumor growth in RCC.

Authors:  Ting Zhang; Xiaohua Niu; Lili Liao; Eun-Ah Cho; Haifeng Yang
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

View more
  11 in total

Review 1.  Gluconeogenesis in cancer cells - Repurposing of a starvation-induced metabolic pathway?

Authors:  Gabriele Grasmann; Elisabeth Smolle; Horst Olschewski; Katharina Leithner
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-05-30       Impact factor: 10.680

2.  PLK1 inhibition selectively induces apoptosis in ARID1A deficient cells through uncoupling of oxygen consumption from ATP production.

Authors:  Upadhyayula S Srinivas; Norbert S C Tay; Patrick Jaynes; Akshaya Anbuselvan; Gokula K Ramachandran; Joanna D Wardyn; Michal M Hoppe; Phuong Mai Hoang; Yanfen Peng; Sherlly Lim; May Yin Lee; Praveen C Peethala; Omer An; Akshay Shendre; Bryce W Q Tan; Sherlyn Jemimah; Manikandan Lakshmanan; Longyu Hu; Rekha Jakhar; Karishma Sachaphibulkij; Lina H K Lim; Shazib Pervaiz; Karen Crasta; Henry Yang; Patrick Tan; Chao Liang; Lena Ho; Vartika Khanchandani; Dennis Kappei; Wei Peng Yong; David S P Tan; Matteo Bordi; Silvia Campello; Wai Leong Tam; Christian Frezza; Anand D Jeyasekharan
Journal:  Oncogene       Date:  2022-03-02       Impact factor: 9.867

3.  Gene-gene interaction analysis incorporating network information via a structured Bayesian approach.

Authors:  Xing Qin; Shuangge Ma; Mengyun Wu
Journal:  Stat Med       Date:  2021-09-20       Impact factor: 2.373

4.  Necroptosis-associated classification combined with tumor microenvironment characteristic analysis of cutaneous melanoma.

Authors:  Gang Hu; Yan Jiang; Jianying Ma; Hui Zhan
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

5.  PLK1 and NOTCH Positively Correlate in Melanoma and Their Combined Inhibition Results in Synergistic Modulations of Key Melanoma Pathways.

Authors:  Shengqin Su; Gagan Chhabra; Mary A Ndiaye; Chandra K Singh; Ting Ye; Wei Huang; Colin N Dewey; Vijayasaradhi Setaluri; Nihal Ahmad
Journal:  Mol Cancer Ther       Date:  2020-11-11       Impact factor: 6.009

6.  Polo-like kinase 1 coordinates biosynthesis during cell cycle progression by directly activating pentose phosphate pathway.

Authors:  Xiaoyu Ma; Lin Wang; Yunyan Li; Dongdong Yang; Tingting Li; Fudong Li; Linchong Sun; Haoran Wei; Kun He; Fazhi Yu; Debiao Zhao; Lan Hu; Songge Xing; Zhaoji Liu; Kui Li; Jing Guo; Zhenye Yang; Xin Pan; Ailing Li; Yunyu Shi; Junfeng Wang; Ping Gao; Huafeng Zhang
Journal:  Nat Commun       Date:  2017-11-15       Impact factor: 14.919

7.  Genetic Manipulation of Sirtuin 3 Causes Alterations of Key Metabolic Regulators in Melanoma.

Authors:  Chandra K Singh; Jasmine George; Gagan Chhabra; Minakshi Nihal; Hao Chang; Nihal Ahmad
Journal:  Front Oncol       Date:  2021-04-16       Impact factor: 6.244

8.  PLK1 Inhibition alleviates transplant-associated obliterative bronchiolitis by suppressing myofibroblast differentiation.

Authors:  Jizhang Yu; Heng Xu; Jikai Cui; Shanshan Chen; Hao Zhang; Yanqiang Zou; Jing Zhao; Sheng Le; Lang Jiang; Zhang Chen; Hao Liu; Dan Zhang; Jiahong Xia; Jie Wu
Journal:  Aging (Albany NY)       Date:  2020-06-15       Impact factor: 5.682

9.  Polo-like kinase 3 inhibits glucose metabolism in colorectal cancer by targeting HSP90/STAT3/HK2 signaling.

Authors:  Baochi Ou; Hongze Sun; Jingkun Zhao; Zhuoqing Xu; Yuan Liu; Hao Feng; Zhihai Peng
Journal:  J Exp Clin Cancer Res       Date:  2019-10-26

Review 10.  Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer.

Authors:  Monika Kressin; Daniela Fietz; Sven Becker; Klaus Strebhardt
Journal:  Cells       Date:  2021-05-12       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.